Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

NIAID Adjuvant Discovery Program

by Global Biodefense Staff
May 13, 2013

Laboratory ResearchThe National Institute of Allergy in Infectious Diseases has renewed a Broad Agency Announcement (BAA) to provide support for the early stage discovery and initial characterization of novel adjuvant candidates.

Research solicited under this acquisition will contribute to the pipeline of new adjuvant leads that either exploit the natural capacity of the innate immune system to initiate and sustain effective T and B cell responses and to induce long term immune memory or act directly on lymphocytes to enhance their response to pathogen-derived antigens.

The design of new adjuvants in this program must include each of the following areas of research:

Identification of novel adjuvant candidates through High Throughput Screening (HTS) approaches and validation that lead compounds stimulate human cells
Determination of the mechanism of action of select lead compounds, including the identification of the receptors the adjuvant candidates work through and the cellular signaling pathways they activate
Optimization of lead adjuvant candidates through formulation and medicinal chemistry, guided by structure-activity relationship (SAR) studies
Verification of the efficacy of lead compounds as vaccine adjuvants in vivo in an animal model

The government anticipates that multiple awards will be made from this solicitation in September 2014.

Further details are available under Solicitation Number: BAA-NIAID-DAIT-NIHAI2013168. The response deadline is October 24, 2013.

Tags: Animal ModelsBAA

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC